DAVITA INC. (DVA) Form 8-K — Aug 4, 2026
DaVita Inc. reported second-quarter 2026 results on August 4, with consolidated revenues of $3.554 billion, operating income of $579 million at a 16.3% margin, and diluted EPS of $4.02 versus $2.58 in the year-ago quarter. Net income attributable to DaVita rose to $265 million from $199 million. Cash generation strengthened, with operating cash flow of $490 million and free cash flow of $256 million for the quarter.
Key figures
- Eps
- 4.02
- Revenue
- 3554084000
- Guidance
- FY2026: adjusted operating income $2,150M-$2,250M; adjusted diluted EPS $14.10-$15.20; free cash flow $1,000M-$1,250M
- Net Income
- 265397000
- Total Debt
- 10848000000
- Debt Amount
- 500000000
- Revenue Yoy
- ≈+5.2% (derived from stated $3,554.1M vs $3,379.5M prior-year quarter)
- Total Assets
- 17709489000
- Cash Position
- 668963000
- Shares Outstanding
- 63955000
- Leverage ratio
- 3.37x (max permitted 5.00x)
- Patients served
- approximately 298,500
- Ltm free cash flow
- 1308000000
- Outpatient centers
- 3,266 (2,671 U.S., 595 in 14 countries)
- Diluted eps q2 2025
- 2.58
- Share repurchases q2
- 2.2 million shares for $348 million at average $154.95
- Effective tax rate q2
- 21.1% (25.6% on income attributable to DaVita Inc.)
- Revenue per treatment
- 415.87
- Free cash flow q2 2026
- 256000000
- Ikc risk based patients
- 64900
- Ltm operating cash flow
- 2193000000
- Operating income q2 2026
- 579001000
- Operating margin q2 2026
- 16.3%
- Us dialysis treatments q2
- 7226600
- Operating cash flow q2 2026
- 490000000
- Ikc annualized medical spend
- 5800000000
- Share repurchases subsequent
- 0.2 million shares for $37 million at average $199.55 (through Aug 4, 2026)
- Net income attributable q2 2025
- 199337000
- Patient care costs per treatment
- 277.4
- Weighted avg effective interest rate
- 5.43%
Price after filing
1 day: -2.2%7 days: -25.3%30 days: -24.9%
Close on the filing date to close N calendar days later (from $238.86). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.